ArticleInternational ophthalmology2025
Efficacy of sulfasalazine on recurrent acute anterior uveitis: a three-year follow-up.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms.Clinical rheumatology · 2026Observational
- Beyond the joints: mechanistic insights and multidisciplinary strategies for spondyloarthritis-associated uveitis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of sulfasalazine (SSZ) for recurrent acute anterior uveitis (AAU).
methodsRetrospective chart review of patients diagnosed with recurrent AAU treated with SSZ from January 2008 to September 2023. The grading of uveitis activity was defined as per SUN working group. The primary outcome was the reduction in the number of uveitis flare-ups over a one-year, two-year and three year-period, compared to pre-treatment year. The response criteria to SSZ were defined as normal ophthalmologic examination. Paired samples Wilcoxon test and Kaplan-Meier survival curve were calculated using R-Commander statistical software (p < 0.05).
resultsFifty-three patients were included. Mean time of follow up was 38.51 ± 38.45 months. Nine patients developed adverse effects to SSZ (16.98%) most of them mild. Ankylosing spondylitis was the most frequent association (n = 28, 52.83%), while HLA-B27 was positive in 69.23% of the patients (n = 36). The most frequent indication for SSZ was based on ocular activity in 52.83% (n = 28). The number of flare-ups dropped from 2.25 (± 1.34) in the pre-treatment year to, 0.81 (± 0.99) at year 1 (p < 0.001), 0.61 (± 0.78) at year 2 (p < 0.001) and 0.65 (± 0.83) at year 3 (p = 0.005). The median time to flare-up of AAU after SSZ was 15.13 months (CI 95, 7.97-27.40).
conclusionOur data point to sulfasalazine as an effective treatment to reduce flare-ups in patients with recurrent non-infectious AAU. Its low cost and good safety profile make it an interesting therapeutic alternative, especially in women of childbearing age.
Indexed as
Identifiers
39853487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.